4-Hydroxyoxyphenbutazone kills both replicating and nonreplicating (NR) Mycobacterium tuberculosis (Mtb), including Mtb resistant to standard drugs. 4-Hydroxyoxyphenbutazone is a potent inhibitor of cytokine production. 4-Hydroxyoxyphenbutazone is an immunosuppressive drug and has the potential for rheumatoid arthritis research.

Fusafungine (Bioparox; Fusaloyos; Locabiotal) is a potent and orally active antibiotic and anti-inflammatory agent. Fusafungine has the potential for the research of upper respiratory airways disease (URAD).

Almurtide (nor-MDP), a muramyl dipeptide derivative with anti-inflammatory and anti-tumor activity. Almurtide also shows protective effects against intraperitoneal Pseudomonas aeruginosa infection or intravenously Candida albicans infection in mice. Almurtide also inhibits the carcinogenic Friend leukemia virus.

Duramycin (Moli1901) is a lantibiotic derived from Streptomyces cinnamoneuma. Duramycin also is a antimicrobial peptide. Duramycin can be used for the research of cystic fibrosis (CF).

Cymal-6 (Cyclohexyl-hexyl-β-D-maltoside) is a potent TEM-1 beta-lactamase inhibitor with an Ki value of 40.05 µM. Cymal-6 (Cyclohexyl-hexyl-β-D-maltoside) can be used as glycosidic surfactant.

Lipid X is a novel monosaccharide precursor of Lipid A (the active moiety of gram-negative endotoxin). Lipid X is protective against endotoxin administered to mice and sheep and against life-threatening gram-negative infections in mice.

Venturicidin B (Aabomycin A2) is a macrolide antibiotic isolated from Streptomyces sp., used as an antifungal agent, a potent inhibitor of the mitochondrial F0-ATP synthase complex.

Decatransin, a fungal cyclic decadepsipeptide, is a protein translocation inhibitor. Decatransin inhibits co- and post-translational translocation across the Sec61/SecYEG translocon.

Rolusafine is an antifungal agent.

L685818 is a specific immunophilin ligand. L685818 was neuroregenerative and non-neuroprotective in primary brain cultures. L685818 protects dopaminergic neurons from toxic inhibition of MPP+ and 6-OHDA, reduces tyrosine hydroxylase (TH) loss, and promotes neuronal process regeneration. L685818 is also an antifungal reagent for Cryptococcus neoformans.

Lagociclovir valactate is a prodrug of Lagociclovir. Lagociclovir valactate is an orally active anti-HBV agent.

trans-ccc_R08 (compound 1-B) is a potent cccDNA (covalently closed circular DMA) inhibitor. trans-ccc_R08 inhibits HBeAg level with an IC50 value of 0.08 µM. trans-ccc_R08 has the potential for the research of Hepatitis B Virus infection (HBV).

cis-ccc_R08 (compound 1) is a flavonoid derivative that can be used in the study of hepatitis B virus (HBV) infection. cis-ccc_R08 is a cccDNA (covalently closed circular DNA) inhibitor.

ccc_R08 is a non-cytotoxic and orally active cccDNA inhibitor that reduces cccDNA levels in the liver of HBV-infected mice. ccc_R08 can be used in the study of HBV virus (hepatitis B virus) infection.

AZT triphosphate (3'-Azido-3'-deoxythymidine-5'-triphosphate) tetraammonium is an active triphosphate metabolite of Zidovudine (AZT). AZT triphosphate tetraammonium exhibits antiretroviral activity and inhibits replication of HIV. AZT triphosphate tetraammonium also inhibits the DNA polymerase of HBV. AZT triphosphate tetraammonium activates the mitochondria-mediated apoptosis pathway.

Carbovir triphosphate (CBV-TP) is a phosphorylated metabolite. Carbovir triphosphate can be used for the research of human immunodeficiency virus (HIV).

Isomitomycin A is a potential inhibitor against SARS-CoV-2. Isomitomycin A targets to the hACE2 binding site of the modelled surface glycoprotein of SARS-CoV-2. Isomitomycin A can be used in studies of COVID-19.

Anhydrotetracycline shows dose-dependent and potent inhibition of tetracycline destructases in vitro.

Amphotericin A is a potent antifungal antibiotic.

Septamycin (A 28695A) is a metal complexing polyether antibiotic. Septamycin is produced by a strain of Streptomyces hygroscopicus NRRL 5678. Septamycin has anticoccidial activity.

Carumonam (AMA-1080; Ro 17-2301) is a sulfonated monocyclic β-Lactam Antibiotic, targeting to penicillin-binding protein (PBP). Carumonam exerts highly activity against Enterobacteriaceae, Pseudomonas aeruginosa, and Haemophilus influenzae, while it weakly and even inactively inhibits Streptococcus pneumoniae and Staphylococcus aureus. Carumonam is resistant to beta-lactamase-mediated hydrolysis.

R-87366 is a water-soluble human immunodeficiency virus (HIV) protease inhibitor. R-87366 has potent inhibitory for HIV protease with a Ki value of 11 nM. R-87366 can be used for the research of anti-human immunodeficiency virus (HIV).

MMV676584 has anti-tuberculosis avtivity. MMV676584 is a novel drug candidate for eumycetoma.

RAY1216 is an orally active SARS-CoV-2 main protease slow-tight inhibitor with a Ki of 8.6 nM.

5-Bromo-2′-deoxy-2′-fluorouridine (Example 1), a 5-halo analog, is potential as an antiviral agent.

EBL-3183, an indole-2-carboxylate, is a potent metallo-β-lactamase (MBL) inhibitor. EBL-3183 is reversibly binding, non-covalent, competitive NDM-1 inhibitor with a pIC50 of 7.7.

BMS-433771 dihydrochloride hydrate is a potent orally active inhibitor of respiratory syncytial virus (RSV). BMS-433771 dihydrochloride hydrate is active against both A and B groups of RSV, with an average EC50 of 20 nM. BMS-433771 dihydrochloride hydrate can be used for the research of respiratory tract disease.

B746 is a clofazimine analog with anti-Mycobacterium avium complex (MAC) activity and is less effective when used with clofazimine or streptomycin.

TBA-7371 (TBA7371, AZ 7371) is a potent, non-covalent inhibitor of decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) with IC50 of 10 nM, an enzyme involved in mycobacterial cell wall biogenesis.

SB-734117 is a human cytomegalovirus (HCMV) replication inhibitor that prevents CREB and histone H3 post-translational modifications.

AM4085 is a potent, orally bioavailable lectin domain of FmLH antagonist with IC50 of 0.19 uM.

BB2-50F is a bactericidal inhibitor of M. tuberculosis with MIC value of 8 uM (H37Rv), inhibits succinate dehydrogenase and the F1Fo-ATP synthase.

BDM71339 is the first small molecule inhibitor of mycobacterial transcriptional regulator EthR, boosts ten times the activity of ethionamide in TB-infected macrophages at low nanomolar concentrations (EC50=72 nM) in vitro.

BDM88855 Hcl is a novel allosteric efflux-pump inhibitor that potentiate antibiotic activity in E. coli through inhibition of its primary RND transporter, AcrAB-TolC.

BDM91288 is a pyridylpiperazine-based AcrB efflux pump inhibitor, potentiate the activity of a panel of antibiotics against K. pneumoniae.

BFA1 is a specific small-molecule activator of Burkholderia FixLJ signaling pathway, inhibit the virulence of multiple pathogenic Burkholderia species.

COE2-2hexyl is a broad-spectrum antibacterial conjugated oligoelectrolyte (COE), does not evoke bacterial resistance, inhibits methicillin-resistant S. aureus (MRSA, MT3302) with MIC of 1 ug/mL.

Cresomycin (CRM) is a bridged macrobicyclic antibiotic via inhibiting bacterial ribosome, shows broad efficacy of CRM against clinical isolates of MDR Gram-negative pathogens differentiates the synthetic macrobicyclic class from traditional lincosamides.

CUO246 (CUO-246) is a potent, selective bacterial DNA gyrase/topoisomerase IV inhibitor, CUO246 is active in vitro against a broad range of Gram-positive, fastidious Gram-negative, and atypical bacterial pathogens.

D66 is a specific small molecule that disrupts S. Typhimurium membrane voltage without cell lysis, prevents S. Typhimurium survival in macrophages (IC50=6.0 uM) and inhibits bacterial growth under conditions that compromise the cell envelope.

DS01750413 is a novel FtsZ inhibitor and new derivative of PC190723 (Cat. PC-47012), inhibits S. aureus FtsZ protein with IC50 of 2 mg/L, has an IC50 of 0.03 mg/L in cell elongation assay of B. subtilis.

EPM35 (Efflux pump modulator 35) is a small molecule that bind AcrB (KD=0.29 uM), inhibit AcrAB-TolC and modulates bacterial efflux pump activity, reduces bacterial intracellular load.

GSK030 (GSK3212030A) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites.

GSK147 (GSK-147) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites (Pf IC50=40 nM).

GSK692 (GSK-692) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites (Pf IC50=10 nM).

HR3744 is a selective small molecule inhibitor of S. aureus exoprotein expression regulator (SaeR) withEC50 of 10 uM in saeP1 promoter assays, reduces expression of hla and other virulence factors.

HSGN-189 is a potent lipoteichoic acid (LTA) biosynthesis inhibitor, exhibits potent antibacterial activity against both MRSA and VRE strains with MICs of 1 ug/mL.

IITR06144 is a novel nitrofuran and exhibits broad-spectrum bactericidal activity against most MDR bacteria (MIC, 0.5 mg/mL).

JBD1 is a small molecule compound that strongly inhibits biofilm formation of S. aureus, including methicillin-resistant strains, induces biofilm inhibition and metabolic remodeling through respiratory activation.

JMV7061 (JMV-7061) is a novel potent, selective bacterial metallo-β-lactamase (MBL) inhibitor, shows submicromolar activities against VIM-type enzymes and strong NDM-1 inhibition (Ki=10-30 nM).

JSF-2414 (JSF2414) is a potent, small molecule GyrB/ParE dual binding inhibitor, simultaneously binds to ATP binding regions of DNA gyrase (GyrB) and topoisomerase (ParE) and displays potent in vitro activity against strains of MRSA, VRSA and VISA.

JSF-2659 is the orally bioavailable, phosphate prodrug of JSF-2414, JSF-2659 (100 and 1 g/kg, p.o.) is highly efficacious in reducing microbial burdens in animal models of Neisseria gonorrhoeae vaginal infection as well as VRSA and C. difficile-induced co

JSF-3269 is a small molecule antibacterial inhibitor against Enterococcus faecium with MIC of 1.9-3.8 uM and minimal bactericidal concentration (MBC) of 7.7-15 uM.

JSF-3285 (JSF3285) is a potent small molecule inhibitor of the M. tuberculosis β-ketoacyl synthase KasA with Kd of 70.7 nM in MST assays, shows activity against H37Rv strain with MIC 0.2 uM.

KKL-55 is a specific small molecule inhibitor of bacterial trans-translation by binding to longation factor thermo-unstable (EF-Tu, Kd=2 uM), inhibits binding between EF-Tu and tmRNA but not between EF-Tu and tRNA, has broad-spectrum antibiotic activity.

KSK67 is a potent small molecule inhibitor of bacterial transcriptional activator PrfA with IC50 of 67 nM, reduces virulence factor expression in L. monocytogene.

LPC-233 (LPC233) is a highly potent and specific inhibitor of UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC (Ki=8.9 pM), specifically inhibits lipid A synthesis and displays outstanding antibiotic activities.

MD-124 is a potent antibiotic adjuvant against Gram-negative bacteria, sensitizes various Gram-negative bacterial species and strains, including multidrug resistant pathogens, toward existing antibiotics.

MMV1091186 (MMV 1091186) is an antimalarial compound that inhibit P. falciparum cytoplasmic isoleucyl tRNA synthetase (cIRS) with IC50 of 0.87 uM.

MMV652103 is an antimalarial imidazopyridazine compound, exerts potent and selective cytotoxicity in ER+ breast cancer cells, potently inhibits the oncogenic PI4KB and PIK3C2G lipid kinases with IC50 of 1.7 and 0.085 uM, respectively.

MSU-43085 is a potent, orally bioavailable inhibitor of Mycobacterium tuberculosis (Mtb, EC50=120 nM) and M. abscessus survival, targets MmpL3.

ND-011992 is a cytochrome bd oxidase (Cyt-bd) inhibitor, inhibits Mycobacterium tuberculosis respiratory complex I with IC50 of 0.12 uM, targets respiratory complex I and bo3 oxidase in addition to bd-I and bd-II oxidases.

NSC116565 is a potent, time-dependent inhibitor of Mycobacterium tuberculosis (M.tb) ketol-acid reductoisomerase (KARI) with Ki of 95.4 nM.

NTB-3119 (NTB3119) is a novel benzothiopyranone derivative and anti-tuberculosis agent with potent in vitro activity against both drug-susceptible and drug-resistant tuberculosis clinical strains.

OTB-658 (OTB658) is a novel oxazolidinone anti-tuberculosis agent, shows potent antibacterial activity against Mycobacterium tuberculosis, especially multi-drug resistant tuberculosis (MDR-TB) in vitro and in vivo.

PKZ18-22 is a potency improved analog of PKZ18, inhibitiong tRNA-regulated gene expression of gram-positive bacteria, shows MIC value of 8 ug/mL against S. aureus.

SAV13 is a selective small molecule inhibitor of S. aureus exoprotein expression regulator (SaeR) withEC50 of 1.06 uM in luciferase assays, reduces expression of hla and other virulence factors.

Savirin (S. aureus virulence inhibitor) is a small molecule inhibitor inhibiting agr quorum sensing in S. aureus by blocking the transcriptional function of AgrA.

SF235 is a small-molecule inhibitor of macrophage infectivity potentiator (Mip) protein with IC50 and Ki 0.42 and 0.29 uM against B. pseudomallei Mip (BpMip) peptidyl-prolyl cis/trans isomerase (PPIase) activity, reduce B. pseudomallei virulence in vitro.

SK-017154-O is a specific and noncompetitive inhibitor of PelA, specifically inhibits PelA esterase activity with IC50 of 11 uM, inhibits Pel-dependent PA14 biofilms with IC50 of 1.8 uM.

SMARt751 is a small molecule that interacts with the transcriptional regulator VirS of M. tuberculosis, up-regulates expression of the mymA operon, reverses resistance to ethionamide both in vitro and in vivo.

SMT-738 is a small-molecule inhibitor of bacterial lipoprotein transport complex (LolCDE), shows potent and highly selective antimicrobial activity.

TBAJ-5307 is a broad spectrum anti-non-tuberculous mycobacteria (NTM) inhibitor targeting FO-domain of F1FO-ATP synthase, shows MIC50 of 4.5 nM and 6 nM against the Mab subsp. abscessus smooth strain and rough strain respectively.

TBI-166 is a potential next-generation antituberculosis riminophenazine with activity against Mycobacterium tuberculosis (0.063  μg/ml).

TPP8 is a small molecule antibacterial inhibiting the ATPase of DNA gyrase with IC50 of 0.3 uM, binds and inhibits the ATPase domain of the gyrase B subunit, shows activity against M. abscessus strains with MIC of 0.04-0.2 uM.

TXA707 is the active metabolite of TXA709 and bacterial protein FtsZ inhibitor, maintains potent activity against S. aureus strains (e.g., MRSA, VRSA, DNSSA, and LNSSA) that are resistant to current SOC antibiotics.

TXA709 is a prodrug of FtsZ-targeting benzamide compound (TXA707) with enhanced metabolic stability, demonstrates improved pharmacokinetic properties, and superior in vivo antistaphylococcal efficacy (both oral and intravenous) relative to previously iden

TXY436 is an N-Mannich base derivative and FtsZ-directed prodrug of PC190723, TXY436 is effective against S. aureus can also target Gram-negative bacteria, such as Escherichia coli.

TXY541 is a 1-methylpiperidine-4-carboxamide prodrug of PC190723 and bacterial protein FtsZ inhibitor, TXY541 is efficacious in vivo in mouse models of systemic infection with both methicillin-sensitive and methicillin-resistant S. aureus.

VU0026921 is a small molecule modulator of metal homeostasis in gram-positive pathogens, disrupts metal homeostasis in multiple Gram-positive bacteria, leading to increased reactive oxygen species and cell death.

NPP-669 (NPP669) is an orally bioavailable cidofovir (CDV) analogue and prodrug, has increased lipophilicity, improved oral absorption, reduced nephrotoxicity, increased cellular uptake, and increased activity against several dsDNA viruses compared to CDV

AG-7404 (AG7404) is a potent, irreversible inhibitor of picornaviral 3C protease, exhibits EC50 values of 80-674 nM against a large panel of programmatically important poliovirus strains.

SJW-2C-227 is a broad-spectrum anti-viral compound that target enterovirus 2C potein, inhibits 2C ATPase activity, exhibits anti-viral activity of SJW-2C-227 with an EC50 of 1.7 µM against EVA71 and 0.52 µM against EV-D68.

ZHSI-1 is a novel inhibitor of Enterovirus 71 (EV71) and Coxsackie A16 (CVA16) replication, interacts with 3D and potently inhibits EV71-induced cell death with IC50 of 3.27 uM.

ZHSI-1 hydrochloride is a novel inhibitor of Enterovirus 71 (EV71) and Coxsackie A16 (CVA16) replication, interacts with 3D and potently inhibits EV71-induced cell death with IC50 of 3.27 uM.

Cotransin CT8 (CT-08) is a substrate-selective co-translational translocation inhibitor, binds the Sec61 translocon to inhibit cotranslational translocation of a subset of secreted and type I transmembrane proteins.

Cotransin CT9 (CT-09) is a substrate-selective co-translational translocation inhibitor, binds the Sec61 translocon to inhibit cotranslational translocation of a subset of secreted and type I transmembrane proteins.

PS3061 (PS 3061) is a substrate-selective co-translational translocation inhibitor, modulates SEC61 translocon and inhibits both DENV and ZIKV virion production and replication.

CWHM-974 is a fluphenazine derivative with antifungal activity against Candida albicans, significantly reduces susceptibility to multidrug transporter-mediated resistance.

FC12406 is a highly potent and broadly active antifungal agent, has MIC of 0.2 ug/mL against Candida albicans.

MMV688766 (MMV 688766) is a small molecule displaying broad-spectrum fungicidal activity through perturbation of lipid homeostasis, inhibits the growth of four geographically distinct C. auris clades with MIC80 of 12.5-50 uM.

NP-BTA is a potent, allosteric inhibitor of C. albicans glutaminyl-tRNA synthetase Gln4 with ITC KD of 180 nM and IC50 of 108 nM, strongly inhibits Candida albicans growth.

NPD6433 is a novel broad-spectrum antifungal agent with MIC <10 ug/mL against C. albicans, Candida glabrata, Candida auris, and C. neoformans, inhibits Fas1 enoyl reductase activity.

YU385599 is a high-affinity inhibitor of fungal pantothenate kinase (PanK), exhibits excellent activity against the human pathogens Candida albicans, C. glabrata, and C. parapsilosis.

DF-006 is a small molecule, orally active Alpha-kinase 1 (ALPK1) agonist, activates ALPK1 and stimulates host innate immunity locally in liver, DF-006 enacts potent anti-HBV responses in mouse models of HBV and in primary human hepatocytes.

E-CFCP is a novel long-acting nucleotide reverse transcriptase inhibitor (NRTI) against HBV, shows potent activity against HBV WTD1 and HBV WTC2 with IC50 of 1.8 and 0.7 nM, respectively.

Neracorvir is a potent anti-HBV agent, targets HBV surface antigen.

SAG-524 (SAG524) is a potent and orally bioavailable small molecule inhibitor of HBV replication, reduces HBsAg and HBV-DNA (IC50 = 0.92 nM and 1.4 nM) by destabilizing HBV-RNA.

ZINC20451377 is a small molecule that binds to hepatitis B surface antigen (HBsAg) with high affinity (Kd=65.3 nM), reduces HBsAg levels and HBV virion secretion in cell culture model for HBV.

GS-9770 is a potent, selective, non-peptidomimetic and orally active HIV protease inhibitor with Ki(app) value of 0.16 nM (recombinant HIV-1 PR).

GSK3839919 is a potent, allosteric HIV-1 integrase inhibitor (ALLINI).

GSK-878 (GSK878) is a highly potent, long-acting inhibitor targeting the HIV-1 capsid with picomolar potency against HIV-1 infection in vitro (EC50=39 pM).

iPAF1C (PAF1C inhibitor) is a first-in-class, specific inhibitor of polymerase-associated factor 1 complex (PAF1C), iPAF1C binds specifically to CTR9 and disrupts of PAF1-CTR9 interaction, enhances HIV-1 latency reversal.

JX-7 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with remarkable inhibitory activity against wild-type HIV-1 (EC50=5 nM) and numerous clinically observed variants in MT-4 cells.

PAV-206 is a novel potent antiretroviral chemotype that inhibits HIV-1 replication with EC50 of 34 nM in HIV-1-infected MT-2 T cells, and 75 nM in HIV-1-infected peripheral blood mononuclear cells (PBMCs), inhibits HIV-1 replication by interfering with HI

SO-7g is a novel highly active HIV-1 nonnucleoside reverse transcriptase inhibitor (NNRTI), exhibits moderate to excellent potency against wild-type HIV-1 with EC50 of 5.3 nM.

TX-1918 (TX1918) is a specific inhibitor of HIV-1 capsid assembly taregting the C-terminal domain of HIV-1 capsid (CA CTD) with IC50 of 3.81 uM, inhibits viral replication (EC50=15.16 μM) and inhibits CA assembly in vitro.

VTD227 is a small molecule Vpr-targeting HIV-1 inhibitor, directly binds to Vpr with Kd of 8.8 uM, inhibits HIV-1 replication in monocyte-derived macrophages (MDM) with IC50 of 0.78 uM.

ANA-0 is a potent inhibitor against the replication of multiple subtypes of influenza A virus, interacts with N-terminal domain of the PA subunit with Kd value of 1.1 uM, and impedes it's endonuclease activity.

dEF3122 is a highly potent small molecule inhibitor of influenza virus replication with IC50 of 3 nM in neuraminidase activity assays, taregts NEET family of protein NAF-1.

ING-1466 is an orally active entry inhibitor of influenza A viruses (IAVs) with EC50 of 0.18 uM against IAV H1N1 (PR8-NS1-Gluc), binds to hemagglutinin (HA) and blocks HA-mediated viral infection.

JJ3297 is a potent antagonist of influenza virus non-structural protein 1 (NS1), strongly restores IFN-β mRNA levels and inhibits viral replication in MDCK cells (IC50=0.8 uM).

NSC125044 is a small molecule inhibitor of the influenza virus protein NS1, inhibits different influenza strains cultured in MDCK-UK cells with IC50 of 7-12 uM.

AWE402 (AWE-402) is a small molecule inhibitor targeting M. tuberculosis cytochrome bcc-aa3 of the electron transport chain (ETC), shows MIC value of 5 nM activity against Mycobacterium tuberculosis H37Rv.

CK-2-63 is a potent first-in-class M. tuberculosis cytochrome bd (cyt bd) inhibitor, demonstrates growth suppression of M. tuberculosis H37Rv with IC50 of 3.7 uM.

CWHM-117 is potent nanomolar inhibitor of the Plasmodium aspartic proteases PM-II and PM-IV with IC50 of 4 and 15 nM respectively, exhibits IC50 of 463 nM in the Pf 3D7 infected RBC assays.

DNDI-6174 is a highly potent inhibitor of Leishmania cytochrome bc1 complex activity, shows broad activity against a panel of representative visceral leishmaniasis clinical isolates from various sources (EC50=10-360 nM).

DSM161 (DSM 161) is a high potent A. baumannii DHODH (AbDHODH) inhibitor, has MIC <1 ug/mL against geographically diverse A. baumannii strains, including meropenem-resistant isolates.

DSM186 (DSM 186) is a high potent A. baumannii DHODH (AbDHODH) inhibitor with IC50 of 28 nM, has MIC <1 ug/mL against geographically diverse A. baumannii strains, including meropenem-resistant isolates.

ELQ-331 (ELQ331) is an alkoxycarbonate prodrug of antimalarial compound ELQ-300 (P. falciparum cytochrome bc1 complex inhibitor), shows P. falciparum IC50 of 6 nM.

Genz-667348 (Genz667348) is a potent, selective P. falciparum DHODH inhibitor with IC50 of 22, 14 and 42 nM for PfDHODH, PbDHODH and PvDHODH, respectively.

Halofuginol (MAZ1805) is a halofuginone analog targeting the Plasmodium falciparum prolyl-tRNA synthetase (PfcPRS, Ki=71.1 nM), is highly active against both liver and asexual blood stages of the malaria parasite (EC50=5.8 nM, P. falciparum 3D7 parasite s

KNX-002 (KNX002) is a potent, specific inhibitor of Toxoplasma gondii class XIV myosin TgMyoA, inhibits TgMyoA ATPase activity with IC50 of 2.8 uM, shows little to no effect on any of the vertebrate myosins.

KNX-115 (KNX115) is a potent, selective inhibitor of plasmodium falciparum myosin A (PfMyoA), inhibits PfMyoA actin-activated ATPase with Ki of 17 nM, >50-fold selectivity against cardiac, skeletal, and smooth muscle myosins.

MBX-2366 (ISG-21) is a potent and specific antimalarial compound with IC50 of 3 nM (P. falciparum growth inhibition), acts directly on plasmodial surface anion channel (PSAC, Target K0.5=2 nM) to quantitatively abolish parasite-induced permeability change

MBX-4055 is a potent and specific antimalarial compound with IC50 of 42 nM (P. falciparum growth inhibition), acts directly on plasmodial surface anion channel (PSAC, Target K0.5=21 nM) to quantitatively abolish parasite-induced permeability changes.

ML276 (ML 276) is a potent, selective inhibitor of Plasmodium falciparum glucose-6-phosphate dehydrogenase (PfG6PDH) with IC50 of 889 nM, with no activity against human G6PD.

ML304 (ML 304) is a potent, selective inhibitor of Plasmodium falciparum glucose-6-phosphate dehydrogenase (PfG6PDH) with IC50 of 190 nM, with no activity against human G6PD (IC50=80 uM).

MMV019266 is a potent antibabesial inhibitor with IC50 of 0.278 uM and 0.909 uM for Babesia spp. (B. bovis and B. divergens), respectively.

MMV396797 is a small molecule inhibitor of the parasite's phosphatidylinositol kinase PfPI4KIIIB, block parasite protein secretion and export.

Nemacol-1 is a small molecule inhibitor of C. elegans vesicular acetylcholine transporter (VAChT), demonstrates nematode-selective activity (C. elegans, EC50=7.1 uM).

OJT008 is a small molecule Mtb. MetAP inhibitor against M. tuberculosis, has MIC50 of 0.063 µg/mL against both active and MDR Mtb.

OSM-S-106 is a reaction hijacking inhibitor of Plasmodium falciparum asparagine tRNA synthetase (PfAsnRS), inhibits the 3D7 line of P. falciparum with IC50 of 58 nM.

P4Q-391 is an antimalarial agent with selective inhibition of the parasite's coenzyme Q cycle, inhibits mitochondrial cytochrome bc1 complex (Cyt bc1).

SCR0911 is a potent malarial cytochrome bc1 inhibitor, inhibits cell growth and ATP synthesis in both the fast- and slow-growing M. smegmatis and M. bovis bacillus Calmette-Guérin, respectively.

T-3767758 is a potent, proline-uncompetitive inhibitor of prolyl-tRNA synthetase (ProRS), displays good activity with EC50 of 595 nM against P. falciparum Dd2-2D4 wild-type parasites.

TCMDC-136879 is a cyclic acyl guanidine compound with antimalarial activity.

TDI-8304 is a highly selective, macrocyclic peptide inhibitor of malaria parasite Plasmodium falciparum proteasome (Pf20S) with IC50 of 0.06 uM, shows high potency against P. falciparum strain Pf 3D7 (EC50=0.009 uM).

UBMC-4 is a potential Trypanosoma cruzi AKT-like pleckstrin homology (PH) domain, exhibits trypanocidal effect on T. cruzi amastigotes with EC50 of 1.85 uM (0.774 ug/mL).

WEHI-518 is a small molecule inhibitor of the parasite's phosphatidylinositol kinase PfPI4KIIIB, shows EC50 of 22 nM against blood-stage P. falciparum parasites.

WEHI-600 is a potent, small molecule inhibitor of the aspartic proteases Plasmepsin X (PMX) with IC50 of 3 nM, possess potent anti-parasitic activity (P. falciparum parasite, IC50=7 nM).

WEHI-601 is a potent, small molecule inhibitor of the aspartic proteases Plasmepsin X (PMX) with IC50 of 5 nM, possess potent anti-parasitic activity (P. falciparum parasite, IC50=9 nM).

WJM228 (WJM-228) is a potent selective inhibitor of P. falciparum cytochrome bc1, targets the Qo site of cytochrome b (cyt b), shows potent parasite activity against P. falciparum 3D7 with EC50 of 19 nM.

ARN1468 is an anti-prion, cellular active small molecule targeting SERPINA3 (ITC KD=26 uM), decreases prion accumulation and reduces PrPSc in the ScGT1 RML cell line with EC50 of 8.64 uM.

OBR-5-340 is a potent, orally bioavailable inhibitor targeting capsid of Rhino- and Enteroviruses,exhibits broad-spectrum antiviral activity against of enteroviruses and rhinoviruses.

AVG-388 is a potent, allosteric, orally efficacious inhibitor of respiratory syncytial virus (RSV) RNA synthesis, potently blocks RSV RNA-dependent RNA polymerase (RdRP) bioactivity, exhibits strong antiviral efficacy in vivo.

JNJ-8003 is a highly potent, selective, non-nucleoside inhibitor of respiratory syncytial virus (RSV) polymerase with IC50 of 0.67 nM, shows EC50 of 0.15 nM in RSV subgenomic replicon assays.

(S)-chlorcyclizine ((S)-CCZ) is an approved antihistamine drug that is related to dichlorcyclizine (DCCZ), inhibits SARS-CoV and SARS-CoV-2 S-mediated infection in MA104 cells with EC50 of 6.91 and 4.09 uM.

AB-00011778 is a small molecule inhibitor of SARS-CoV-2 entry and the Spike/ACE2 interaction, inhibits viral replication with EC50 of 250 nM in A549-ACE2 cells, AB-00011778 is equally effective in impairing the S/ACE2 association in the different mutants.

AC1115 is a potent, selective, next-generation antiviral targeting SARS-CoV-2 Mpro and host lysosomal cysteine protease cathepsin L (CTSL) with high antiviral activity, AC1115 is the active form of Olgotrelvir.

Acriflavine (Acriflavin) is a topical antiseptic that found to be a potent papain-like protease (PLpro) inhibitor, inhibits SARS-CoV-2 and other betacoronaviruses.

ALG-097111 is a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease (3CLpro) with IC50 of 7 nM, without effect against human cathepsin L (IC50>10 uM).

Cyanorona-20 is a potent and specific SARS-CoV-2 inhibitor with very high selectivity (209- and 45-fold more potent than favipiravir and remdesivir, respectively), effectively binds to and inhibits the SARS-CoV-2 RdRp.

D-4-77 is a potent, covalent peptidyl inhibitor of SARS-CoV-2 main protease (Mpro) with IC50 of 0.95 uM and antiviral EC50 of 0.49 uM.

Difluorobenztropine (AHN 1-055) is a direct-acting SARS-CoV-2 entry inhibitor that targets the SARS-CoV-2 spike fusion peptide domain.

DMGA is an allosteric and covalent inhibitor of SARS-CoV-2 papain-like protease (SARS-CoV-2 PLpro) with IC50 of 9.4 uM, covalently binds with C270 of the SARS-CoV-2 PLpro.

DS0464 is a selective, bisubstrate competitive inhibitor SARS-CoV-2 nonstructural protein 14 (nsp14) with IC50 of 1.1 uM, also selective against 28 out of 33 RNA, DNA, and protein MTases.

EIDD-2801 (MK-4482, Molnupiravir) is a highly potent ribonucleoside analog, and prodrug of EIDD-1931, exhibits broad-spectrum antiviral inhibitor of multiple RNA viruses including SARS-CoV-2.

GC-14 is a potent, selective and non-covalent non-peptide SARS-CoV-2 main protease (Mpro) inhibitor with IC50 of 0.4 uM, displays excellent selectivity over cathepsins B, F, K, L, and caspase 3 (IC50>50 uM).

GC373 is a potent, covalent inhibitor of SARS CoV-2 main protease (MPro) with Kd of 0.15 uM, the reactive aldehyde form of GC376.

GC-78-HCl is a potent nonpeptide SARS-CoV-2 main protease (Mpro) inhibitor with IC50 of 0.19 uM, exhibits excellent antiviral activity (EC50=0.4 uM).

JC19 is a a cysteine-reactive small molecule degrader of SARS-CoV-2 nsp14 with DC50 of 8.7 uM in HEK293T cells.

JMX0286 is a potent, specific and allosteric inhibitor against SARS-CoV-2 3CLpro with IC50 of 4.8 uM in FRET based screening assays, shows strong inhibition of SARS-CoV-2 virus with EC50 of 2.25 uM in A549-hACE2 cells.

Jun9-57-3R is a potent, selective, covalent SARS-CoV-2 Mpro inhibitor with IC50 of 0.05 uM.

Jun9-62-2R is a potent, selective, covalent SARS-CoV-2 Mpro inhibitor with IC50 of 0.43 uM.

Jun9-88-6R is a potent, selective, covalent SARS-CoV-2 Mpro inhibitor with IC50 of 0.08 uM.

KSL-128114 (KLS 128114) is a highly potent and metabolically stable peptide inhibitor that binds to the PDZ1 domain of syntenin (KD=0.3 uM), inhibits SARS-CoV-2 infection by blocking the endosomal entry of the virus.

MAC-5576 (MAC5576) is a small molecule, covalent inhibitor of coronavirus SARS-CoV 3CLpro with IC50 of 0.5 uM, inhibits SARS-CoV-2 3CL protease with IC50 of 0.093 uM.

MAT-POS-e194df51-1 is potent, selective and noncovalent SARS-CoV-2 main protease (SARS-CoV-2 Mpro) inhibitor with IC50 of 36.8 nM, shows antiviral activity with EC50 of 64 nM in A549-ACE2-TMPRSS2 cells.

MDOLL-0229 is a selective small molecule inhibitor for SARS-CoV-2 Mac1 with IC50 of 2.1 uM, inhibits coronavirus replication.

MI-30 (SARS-CoV-2 Mpro inhibitor MI-30) is a potent, selective SARS-CoV-2 Mpro inhibitor with IC50 of 17.2 nM.

MK-7845 is a potent, reversible covalent SARS-CoV-2 3CLPro inhibitor with IC50 of 8.7 nM, inhibits wild-type SARS-CoV-2 3CLPro in SARS-CoV-2 reporter replicon assay in A549 cells with IC50 of 15 nM.

ML300 (ML 300) is a potent, selective, noncovalent inhibitor of the SARS-CoV 3CL protease (3CLpro) with IC50 of 4.11 uM, inhibits SARS-CoV-2 3CLpro with IC50 of 4.99 uM.

Molnupiravir N-1 is an impurity chemical of Molnupiravir (EIDD-2801, MK4482), which is anti-SARS-CoV-2 for treatment of COVID-19.

MPI8 is a highly potent SARS-CoV-2 main protease (MPro) inhibitor with IC50 of 8.5 nM.

MPI8 is a highly potent SARS-CoV-2 main protease (MPro) inhibitor with IC50 of 33 nM, completely prevented the SARS-CoV-2-induced cytopathogenic effect in Vero E6 cells at 2.5-5 uM and A549 cells at 0.16-0.31 uM.

MU-UNMC-1 is a potential small-molecule inhibitor of S-RBD and ACE-2 interaction, shows antiviral activity against SARS-CoV-2 with IC50 of 0.67 uM in human bronchial epithelial cells.

MU-UNMC-2 is a potential small-molecule inhibitor of S-RBD and ACE-2 interaction, shows antiviral activity against SARS-CoV-2 with IC50 of 1.72 uM in human bronchial epithelial cells.

NACE2i is a cell permeable, specific and selective peptide inhibitor of nuclear ACE2, inhibits binding between IMP1α and ACE2 and SARS-CoV-2 viral replication. NACE2i specifically targets nuclear ACE2 and not other nuclear proteins targeted by the importin pathway. NACE2i has no impact on ACE2 enzymatic activity. NACE2i prevents inflammation and macrophage infiltration, and increases NK cell infiltration in bronchioles. NACE2i treatment increases the levels of the active histone mark, H3K27ac, restores host translation in infected hamster bronchiolar cells, and leads to an enrichment in methylated ACE2 in hamster bronchioles and lung macrophages. NACE2i has a dual mode of action: suppressing the lethal inflammation in severe COVID-19 and inhibiting viral replication by restoring host translation of anti-viral cytokines.

NBCoV1 is a highly potent small molecule viral fusion inhibitor with potential pan-Coronavirus activity (SARS-CoV IC50=17 nM, SARS-CoV-2 IC50=51 nM, MERS-CoV IC50=75 nM, cell-based single-cycle assays).

NBCoV2 is a highly potent small molecule viral fusion inhibitor with potential pan-Coronavirus activity (SARS-CoV IC50=13.8 nM, SARS-CoV-2 IC50=22.8 nM, MERS-CoV IC50=77 nM, cell-based single-cycle assays). NBCoV2 also has potent antiviral activity against all mutant pseudoviruses carrying single-, double-, or triple-mutations featured in the B.1.1.7 UK, B.1.351 RSA, and B.1.617.2 Delta variants (IC50=30-80 nM). NBCoV2 completely preventing the induction of any virus-induced CPE (IC100=1.25 uM, SARS-CoV-2 (US_WA-1/2020)). NBCoV2 bind to the S2 subdomain of the SARS-CoV-2 trimer, thus, inhibits the fusion of CoVs with the cell membran, and is specific for the SARS-CoV-2 S protein.

NSC 621601 (Compound Q34) is a potent, specific inhibitor of SARS-CoV-2 cellular entry with IC50 of 15 uM.

Olgotrelvir (STI-1558) is a next-generation antiviral targeting SARS-CoV-2 Mpro and host lysosomal cysteine protease cathepsin L (CTSL) with high antiviral activity, Olgotrelvir is the prodrug of AC1115.

P2119 (P-2119) is an anticoronaviruse chemical probe that inhibit SARS-CoV-2 Spike binding to human ACE2 receptor.

P2165 (P-2165) is a anticoronaviruse chemical probe that inhibit SARS-CoV-2 Spike binding to human ACE2 receptor.

PAV-104 (PAV104) is a novel viral assembly inhibitor, shows potent anti-SARS-CoV-2 activity in Calu-3 cells with EC50 of 1.7 nM and EC90 of 23.5 nM, inhibits the oligomerization of the SARS-CoV-2 nucleocapsid.

Pomotrelvir (PBI-0451) is a potent competitive inhibitor of SARS-CoV-2 Mpro (Ki=2.7 nM) with high selectivity against human proteases, inhibits wild-type SARS-CoV-2 Mpro with IC50 of 24 nM.

SB27012 (SB 27012) is a small molecule PPI inhibitor of the Spike RBD-ACE2 interaction (IC50=7.7 uM in ELISA assays), binds ACE2 (Kd=210 nM) without affecting ACE2 enzymatic activity.

SCoV2 Plpro-Probe-7 is a peptidomimetic activity probe and substrate for SCoV2 PLpro, exhibits excellent sensitivity to wild-type (WT) SCoV2 PLpro, but not to the catalytically inactive mutant, SCoV2 PLproC112S, consists of a fluorogenic HCC conjugated to

Simnotrelvir (SSD8432, SIM0417) is a potent, selective, covalent and orally bioavailable SARS-CoV-2 3C-like protease (3CLpro) inhibitor with IC50 of 9 nM in enzymatic inhibition assays.

Titanocene dichloride (Cp2 TiCl 2) is an active inhibitor of interaction between SARS-CoV-2 spike (S) protein with the ACE2 receptor (IC50=3.9 uM)

TKB245 (TKB-245) is a potent, specific SARS-CoV-2 Mpro inhibitor with IC50 of 7 nM, exhibits highly potent anti-SARS-CoV-2 activity with EC50 and EC95 values of 0.03 and 0.53 µM, respectively.

TKB248 (TKB-248) is a potent, specific SARS-CoV-2 Mpro inhibitor with IC50 of 74 nM, exhibits highly potent anti-SARS-CoV-2 activity with EC50 and EC95 values of 0.22 and 0.87 µM, respectively.

VE607 is a specific small molecule inhibitor that block S protein-ACE2-mediated cellular entry of the SARS-CoV, inhibits pseudovirus entry with EC50 of 3 μM and inhibited SARS-CoV plaque formation with EC50 of 1.6 μM.

WNN2048-F004 (Compound 4a) is a potent, covalent, nonpeptidomimetic SARS-CoV-2 main protease (Mpro) inhibitor with biochemical IC50 of 103 nM, covalently binds to the substrate-binding pocket (Cys145) of SARS-CoV-2 Mpro.

WU-04 is a highly potent, non-covalent, orally active inhibitor of SARS-CoV-2 3C-like protease (3CLpro) with IC50 of 72 nM, binding Kd of 37 nM.

Y180 is a highly potent, selective, covalent, and orally active SARS-CoV-2 main protease (Mpro) inhibitor with IC50 of 8.1 nM in enzymatic assays, binding Ki value of 1 nM.

Z222979552 is a small molecule non-covalent SARS-CoV-2 Mpro inhibitor with IC50 of 1.0 uM.

Z8539_0072 is a potent SARS-CoV-2 macrodomain inhibitor that binds to the NSP3 macrodomain of SARS-CoV-2 (Mac1) with IC50 of 460 nM.

EIDD-1931 (Beta-d-N4-hydroxycytidine, β-d-N4-hydroxycytidine, NHC) is an active metabolite of EIDD-2801 with broad-spectrum antiviral inhibitor of SARS-CoV-2.